J&J In-Stent Restenosis Pilot Study Could Challenge Brachytherapy
This article was originally published in The Gray Sheet
Executive Summary
A Johnson & Johnson/Cordis pilot study of drug-coated stents in treating in-stent restenosis potentially opens the door for a competitor to intravascular radiation
You may also be interested in...
Novoste Outlines Plan To Weather Coming Flood Of Drug-Coated Stents
Novoste will acquire several new vascular intervention products to sustain its sales force in 2003 and 2004, when new drug-coated stents are expected to quell demand for the company's Beta-Cath coronary brachytherapy system, the firm reported Jan. 10 at the JP Morgan Healthcare Conference in San Francisco
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.